Protagonist Therapeutics, Inc. Forecast, price target & analysts
Protagonist Therapeutics, Inc. Target price 2026 - Analyst rating & recommendation
Protagonist Therapeutics, Inc. Classifications & Recommendation
Protagonist Therapeutics, Inc. Price Target
| Target Price | $173.40 |
| Price | $141.86 |
| Potential |
22.23%
register free of charge
|
| Number of Estimates | 16 |
|
16 Analysts have issued a price target Protagonist Therapeutics, Inc. 2027 .
The average Protagonist Therapeutics, Inc. target price is $173.40.
This is
22.23%
register free of charge
$236.25
66.54%
register free of charge
$151.50
6.80%
register free of charge
|
|
| A rating was issued by 20 analysts: 19 Analysts recommend Protagonist Therapeutics, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Protagonist Therapeutics, Inc. stock has an average upside potential 2027 of
22.23%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 46.02 | 556.09 |
| 89.41% | 1,108.37% | |
| EBITDA Margin | -340.83% | 56.12% |
| 678.97% | 116.47% | |
| Net Margin | -282.81% | 53.73% |
| 546.46% | 119.00% |
16 Analysts have issued a sales forecast Protagonist Therapeutics, Inc. 2026 . The average Protagonist Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Protagonist Therapeutics, Inc. EBITDA forecast 2026. The average Protagonist Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
16 Protagonist Therapeutics, Inc. Analysts have issued a net profit forecast 2026. The average Protagonist Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.05 | 4.62 |
| 148.46% | 325.37% | |
| P/E | 30.70 | |
| EV/Sales | 15.10 |
16 Analysts have issued a Protagonist Therapeutics, Inc. forecast for earnings per share. The average Protagonist Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Protagonist Therapeutics, Inc....
Current Protagonist Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BMO Capital |
Locked
➜
Locked
|
Locked | Sep 01 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Sep 01 2026 |
| Citigroup |
Locked
➜
Locked
|
Locked | Aug 31 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 31 2026 |
| BMO Capital |
Locked
➜
Locked
|
Locked | Aug 17 2026 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Aug 10 2026 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Aug 10 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
BMO Capital:
Locked
➜
Locked
|
Sep 01 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Sep 01 2026 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Aug 31 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 31 2026 |
|
Locked
BMO Capital:
Locked
➜
Locked
|
Aug 17 2026 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Aug 10 2026 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Aug 10 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
